Equillium vs Q32 Bio
EQ and QTTB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EQ and QTTB compare
Q32 Bio is the larger company, worth 3.2 times as much as Equillium ($259M against $81.8M).
Q32 Bio scores higher on the StockData Score (11 against 8 for Equillium), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EQ | QTTB |
|---|---|---|
| Size and price | ||
| Market cap | $81.8M | $259M |
| Share price | $1.29 | $8.71 |
| Change, 1 year | 39.6% | 258% |
| Change, 5 years | −75.4% | −90.6% |
| Beta (5Y) | 0.42 | 0.67 |
| Employees | 14 | 24 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.6× | 0.9× (better) |
| EV/EBITDA | – | −1.6× |
| FCF yield | −18.9% | – |
| Fair value | – | $20.33 |
| Margin of safety | – | 57.1% |
| Growth | ||
| Revenue growth, 5Y average | – | 81.9% |
| Profitability | ||
| Return on equity | −43.9% | 24.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 19.49 | 56.34 (better) |
| Altman Z-score | 9.83 | 16.60 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −4.0% |
| Shareholder yield | 0.00% (better) | −4.0% |
| Ownership | ||
| Held by institutions | 65.8% | 74.6% |
| Held by insiders | 7.6% | 28.9% |
| Insider net buying, 12 months | −$2.7M | $29.5M (better) |
| Short interest, % of float | 10.1% | 26.4% |
Go deeper
- EQ stock overview
- EQ income statement
- EQ valuation and score
- QTTB stock overview
- QTTB income statement
- QTTB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.